Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Exagen (XGN) Return on Sales (2018 - 2025)

Historic Return on Sales for Exagen (XGN) over the last 8 years, with Q3 2025 value amounting to 0.41%.

  • Exagen's Return on Sales fell 100.0% to 0.41% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.3%, marking a year-over-year change of 0.0%. This contributed to the annual value of 0.27% for FY2024, which is 1800.0% up from last year.
  • Latest data reveals that Exagen reported Return on Sales of 0.41% as of Q3 2025, which was down 100.0% from 0.26% recorded in Q2 2025.
  • In the past 5 years, Exagen's Return on Sales ranged from a high of 0.2% in Q2 2024 and a low of 1.93% during Q2 2022
  • Moreover, its 5-year median value for Return on Sales was 0.41% (2025), whereas its average is 0.57%.
  • Its Return on Sales has fluctuated over the past 5 years, first crashed by -14300bps in 2022, then surged by 15700bps in 2023.
  • Quarter analysis of 5 years shows Exagen's Return on Sales stood at 0.56% in 2021, then plummeted by -112bps to 1.18% in 2022, then skyrocketed by 66bps to 0.4% in 2023, then skyrocketed by 32bps to 0.28% in 2024, then crashed by -49bps to 0.41% in 2025.
  • Its Return on Sales was 0.41% in Q3 2025, compared to 0.26% in Q2 2025 and 0.24% in Q1 2025.